fgfr4 antagonist incb062079
Generic: FGFR4 Antagonist INCB062079
fgfr4 antagonist incb062079: 1 clinical trial tracked.
fgfr4 antagonist incb062079 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about fgfr4 antagonist incb062079, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Primary endpoint: Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs)
Interventionalopen25 targetStarted 2017-05Completion 2020-066 sites · Belgium, United StatesIncyte Corporation